* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Amphastar Pharmaceuticals's PEG Ratio or its related term are showing as below:
AMPH'
s PEG Ratio Range Over the Past 10 Years
Min: 0.14 Med: 0.27 Max: 3.37
Current: 0.17
During the past 13 years, Amphastar Pharmaceuticals's highest PEG Ratio was 3.37. The lowest was 0.14. And the median was 0.27.
AMPH's PEG Ratio is ranked better than 97.59% of 374
companies
in the Drug Manufacturers industry
Industry Median: 1.655
vs AMPH: 0.17
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Amphastar Pharmaceuticals PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amphastar Pharmaceuticals's PEG Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals's PEG Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's PEG Ratio falls into.
Amphastar Pharmaceuticals PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Amphastar Pharmaceuticals (NAS:AMPH) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Amphastar Pharmaceuticals PEG Ratio Related Terms
Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMPH has been successfully added to your 